DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK. et al.
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840.
J Clin Oncol 2008;
26: 1642-9
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.